Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects
Purpose Bone diseases account for an enormous cost burden on health systems. Bone disorders are considered as age-dependent diseases. The aging of world population has encouraged scientists to further explore the most effective preventive modalities and therapeutic strategies to overcome and reduce the high cost of bone disorders. Herein, we review the current evidence of melatonin’s therapeutic effects on bone-related diseases. Methods This review summarized evidences from in vitro, in vivo, and clinical studies regarding the effects of melatonin on bone-related diseases, with a focus on the molecular mechanisms. Electronically, Scopus and MEDLINE®/PubMed databases were searched for articles published on melatonin and bone-related diseases from inception to June 2023. Results The findings demonstrated that melatonin has beneficial effect in bone- and cartilage-related disorders such as osteoporosis, bone fracture healing, osteoarthritis, and rheumatoid arthritis, in addition to the control of sleep and circadian rhythms. Conclusion A number of animal and clinical studies have indicated that various biological effects of melatonin may suggest this molecule as an effective therapeutic agent for controlling, diminishing, or suppressing bone-related disorders. Therefore, further clinical studies are required to clarify whether melatonin can be effective in patients with bone-related diseases..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Osteoporosis international - 34(2023), 10 vom: 02. Juli, Seite 1677-1701 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bagherifard, Abolfazl [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Chondrosarcoma |
|---|
| Anmerkungen: |
© International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00198-023-06836-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2145637621 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2145637621 | ||
| 003 | DE-627 | ||
| 005 | 20240118105821.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00198-023-06836-1 |2 doi | |
| 035 | |a (DE-627)OLC2145637621 | ||
| 035 | |a (DE-He213)s00198-023-06836-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Bagherifard, Abolfazl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose Bone diseases account for an enormous cost burden on health systems. Bone disorders are considered as age-dependent diseases. The aging of world population has encouraged scientists to further explore the most effective preventive modalities and therapeutic strategies to overcome and reduce the high cost of bone disorders. Herein, we review the current evidence of melatonin’s therapeutic effects on bone-related diseases. Methods This review summarized evidences from in vitro, in vivo, and clinical studies regarding the effects of melatonin on bone-related diseases, with a focus on the molecular mechanisms. Electronically, Scopus and MEDLINE®/PubMed databases were searched for articles published on melatonin and bone-related diseases from inception to June 2023. Results The findings demonstrated that melatonin has beneficial effect in bone- and cartilage-related disorders such as osteoporosis, bone fracture healing, osteoarthritis, and rheumatoid arthritis, in addition to the control of sleep and circadian rhythms. Conclusion A number of animal and clinical studies have indicated that various biological effects of melatonin may suggest this molecule as an effective therapeutic agent for controlling, diminishing, or suppressing bone-related disorders. Therefore, further clinical studies are required to clarify whether melatonin can be effective in patients with bone-related diseases. | ||
| 650 | 4 | |a Chondrosarcoma | |
| 650 | 4 | |a Ewing’s sarcoma | |
| 650 | 4 | |a Fibromyalgia | |
| 650 | 4 | |a Giant cell tumor | |
| 650 | 4 | |a Gout | |
| 650 | 4 | |a Melatonin | |
| 650 | 4 | |a Osteoarthritis | |
| 650 | 4 | |a Osteoporosis | |
| 650 | 4 | |a Osteosarcoma | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 700 | 1 | |a Hosseinzadeh, Azam |4 aut | |
| 700 | 1 | |a Koosha, Fereshteh |4 aut | |
| 700 | 1 | |a Sheibani, Mohammad |4 aut | |
| 700 | 1 | |a Karimi-Behnagh, Arman |4 aut | |
| 700 | 1 | |a Reiter, Russel J. |4 aut | |
| 700 | 1 | |a Mehrzadi, Saeed |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Osteoporosis international |d Springer London, 1990 |g 34(2023), 10 vom: 02. Juli, Seite 1677-1701 |w (DE-627)170488306 |w (DE-600)1064892-6 |w (DE-576)032851979 |x 0937-941X |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:10 |g day:02 |g month:07 |g pages:1677-1701 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00198-023-06836-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 10 |b 02 |c 07 |h 1677-1701 | ||